<DOC>
	<DOCNO>NCT00498901</DOCNO>
	<brief_summary>RATIONALE : Aromatase inhibitor , letrozole , prevent formation estradiol , female hormone . Giving letrozole together goserelin , leuprolide , surgery may effective treatment woman hormone-dependent breast cancer . PURPOSE : This phase II trial study well give letrozole together goserelin leuprolide work treat premenopausal estrogen receptor-positive patient stage IV breast cancer .</brief_summary>
	<brief_title>Letrozole Goserelin Leuprolide Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To measure overall response rate ( ORR ) premenopausal woman treat aromatase inhibitor ( AI ) ovarian suppression ( OS ) . Secondary - To measure time treatment failure ( TTF ) premenopausal woman treat AI OS . - To measure time progression ( TTP ) premenopausal woman treat AI OS . - To measure time death premenopausal woman treat AI OS . - To assess clinical benefit rate ( CBR ) premenopausal woman treat AI OS . - To measure qualitative quantitative toxicity AI OS . - To determine whether ORR , TTP , CBR similar see postmenopausal woman treat AI . - To determine whether ORR , TTP , CBR similar see premenopausal woman treat tamoxifen OS . - To determine level estrogen ( i.e. , estradiol estrone ) adequately suppress premenopausal woman AI OS . OUTLINE : This pilot , open-label study . Patients undergo surgical ovarian suppression ( OS ) medical OS luteinizing hormone-releasing hormone ( LHRH ) agonist ( i.e. , goserelin leuprolide acetate , intramuscularly monthly 3 month every 2 month thereafter duration study therapy ) . Beginning day 14 initiation LHRH-agonist therapy surgery , patient receive oral letrozole daily . Treatment continue absence disease progression unacceptable toxicity . Menopausal status test periodically study measure serum estradiol level . Patients convert menopausal state first month study therapy , receive high dose LHRH undergo repeat estradiol test second month . If patient continue premenopausal , consider bilateral salpingo-oophorectomy remove study . After completion study therapy , patient follow every 3 month 2 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm carcinoma breast Metastatic disease Measurable disease ( i.e. , unidimensional RECIST ) No rapidly progress visceral involvement ( e.g. , liver lymphangitic lung disease ) No know marrow involvement evidence diffuse uptake image study bone marrow biopsy aspirate No evidence CNS metastases Estrogen and/or progesteronereceptor positive status confirm primary breast tumor recent biopsy metastatic site PATIENT CHARACTERISTICS : Female Premenopausal* , define follow criterion : Less 12 month last menstrual period premenopausal estradiol within past 12 month No prior bilateral oophorectomy 45 year old young intact ovary candidate aromatase inhibitor therapy alone due potential recurrent ovarian function NOTE : *Women consider premenopausal prior hysterectomy intact ovary follicular hormone level consistent institutional normal value premenopausal state Women meeting premenopausal criterion prior receive ovarian suppression eligible ECOG performance status 02 Life expectancy ≥ 3 month Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonhormonal contraception 12 week discontinuation study therapy ANC ≥ 500 cells/mm³ Platelet count ≥ 50,000 cells/mm³ Hematocrit ≥ 28 % In absence liver metastasis : AST ALT ≤ 2.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN In presence liver metastasis : AST ALT ≤ 5 time ULN Alkaline phosphatase ≤ 5 time ULN In presence bone metastasis : AST ALT ≤ 10 time ULN Alkaline phosphatase ≤ 10 time ULN Total bilirubin ≤ 2 time ULN No significant comorbid condition , include follow : Clinically significant cardiac disease well control medication ( e.g. , congestive heart failure , symptomatic coronary artery disease , cardiac arrhythmia ) Myocardial infarction within past 12 month Serious concurrent infection No lack physical integrity upper gastrointestinal tract No inability swallow malabsorption syndrome No carcinoma within past 5 year except nonmelanoma skin cancer treat situ cervical cancer No mental illness No known hypersensitivity luteinizing hormonereleasing hormone ( LHRH ) , LHRHagonist analogue , component goserelin PRIOR CONCURRENT THERAPY : No concurrent chemotherapy and/or additional hormonal therapy Concurrent trastuzumab ( Herceptin® ) patient HER2 overexpression allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>